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A B S T R A C T
Autosomal dominant polycystic kidney disease (ADPKD) is
characterized by progressive cyst formation, leading to growth
in kidney volume and renal function decline. Although thera-
pies have emerged, there is still an important unmet need for
slowing the rate of disease progression in ADPKD. High intra-
cellular levels of adenosine 30,50-cyclic monophosphate (cAMP)
are involved in cell proliferation and fluid secretion, resulting in
cyst formation. Somatostatin (SST), a hormone that is involved
in many cell processes, has the ability to inhibit intracellular
cAMP production. However, SST itself has limited therapeutic
potential since it is rapidly eliminated in vivo. Therefore ana-
logues have been synthesized, which have a longer half-life and
may be promising agents in the treatment of ADPKD. This re-
view provides an overview of the complex physiological effects
of SST, in particular renal, and the potential therapeutic role of
SST analogues in ADPKD.
Keywords: ADPKD, cAMP, renal physiology, somatostatin,
somatostatin analogues
I N T R O D U C T I O N
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common inherited kidney disease, with a prevalence of 3–
4/10 000 in the general population [1]. ADPKD is characterized
by progressive development and growth of numerous renal
cysts. This eventually leads to end-stage renal disease in 70% of
affected patients at a median age of 58 years. An important extra-
renal manifestation is progressive cyst formation in the liver,
with a radiological prevalence of 95% by the age of 35–45 years,
which leads to symptoms in 20% of cases [2, 3]. Symptoms in
patients with polycystic liver disease (PLD) arise from the en-
larged intra-abdominal volume and include abdominal disten-
sion, early satiety, herniations, dyspnoea and pain. In a limited
number of affected subjects, liver transplantation is necessary [4].
For a long time there were no therapies to slow the rate of
disease progression in ADPKD. In the last two decades, how-
ever, novel insight into the pathophysiology of ADPKD has led
to the discovery of possible targets for treatment. One of these
targets is adenosine 30,50-cyclic monophosphate (cAMP), which
is elevated in ADPKD due to disrupted intracellular calcium
homoeostasis and results in progressive cyst formation in both
kidneys [5]. Therapeutic agents that interfere in this pathway
can possibly attenuate ADPKD disease progression. The vaso-
pressin V2 receptor antagonist tolvaptan, which down-regulates
cAMP, is effective in the treatment of ADPKD [6, 7]. However,
the effect of tolvaptan seems limited to renal tubular cells in the
distal nephron and collecting duct, which express the V2 recep-
tor. Cysts originating from other nephron segments as well as
liver cysts will probably not be affected, although a recent exper-
imental study has suggested that vasopressin V2 receptors are
present on biliary cells [8]. However, it has not been shown that
tolvaptan affects liver volume in ADPKD. Moreover, aquaretic
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side effects limit widespread clinical use of this drug. Therefore
there is still an unmet need for new therapies to slow disease
progression in ADPKD.
Somatostatin (SST) is a hormone that is involved in many
cell processes and directly and indirectly inhibits cAMP pro-
duction in various tissues, including liver and kidney. SST ana-
logues therefore have a potential role in the treatment of
ADPKD for the renal as well as the hepatic phenotype. Studies
about SST and its complex signalling pathway mainly date from
the 1980s and 1990s. This review provides a summary of the
role of SST and SST analogues in physiology, with a focus on the
renal effects, and in the pathophysiology of ADPKD. The he-
patic effects of SST have recently been reviewed elsewhere [9].
H I S T O R Y O F S S T
Somatostatin (SST or SRIF) was first discovered in 1968 by
Krulich et al. [10] as a growth hormone–inhibiting factor pro-
duced by the hypothalamus. A year later, Hellman and
Lernmark [11] found an insulin-inhibiting factor produced by
the pancreas. In 1973, Brazeau et al. [12] concluded that these
phenomena were caused by the same hormone: SST. After its
discovery, subsequent studies revealed that SST is more widely
produced throughout the body and induces a broad spectrum
of biological effects, but mainly inhibitory.
T H E P H Y S I O L O G Y O F S S T
SST
SST is synthesized as part of a large precursor protein, pre-
prosomatostatin (preproSST), which is rapidly processed into
prosomatostatin (proSST). This prohormone is enzymatically
processed mainly at the C-terminal segment to generate two
bioactive forms, SST-14 and SST-28 (Figure 1) [13]. ProSST
can also be cleaved at other sites, which creates four more cleav-
age products, but whether these latter cleavage products have a
physiological function remains uncertain [14].
Secretion of SST
SST is produced by different cell types. Most SST-producing
cells are found throughout the central and peripheral nervous
systems, as well as in the pancreas and gastrointestinal tract.
SST-producing cells are also found, although in smaller num-
bers, in other organs, including the kidney. About 65% of the
total body SST is derived from the gastrointestinal tract, 25%
from the central nervous system, 5% from the pancreas and 5%
from the remaining organs [15]. Secretion of SST is either stim-
ulated or inhibited by a broad spectrum of agents, including
ions, nutrients, peptides, neurotransmitters, hormones, growth
factors and cytokines. Some of these agents exert common
effects on SST cells at different locations, whereas others appear
to induce tissue selective effects. For example, nutrients, like
glucose, stimulate SST secretion by d-cells of the pancreas but
inhibit SST secretion by cells of the hypothalamus [15].
SST receptors and their activation
SST can act on multiple cellular targets via a family of five
receptors: SST receptor (SSTR) 1–5 [15]. The SST receptor
subtypes are more or less of equal size and consist of seven a he-
lical transmembrane domain, G protein-coupled receptor pro-
teins. Typically, more than one receptor subtype is expressed in
a single organ. All receptor subtypes have nanomolar affinity
for SST-14 and SST-28, but SSTR1–4 have higher selectivity for
SST-14, whereas SSTR5 has a higher selectivity for SST-28 [13].
Ligand binding to these receptors generally results in three
effects: inhibition of secretion, inhibition of cell proliferation
and induction of apoptosis. Ligand binding to any of the five re-
ceptor subtypes first results in activation of the inhibitory G-
protein (Gi), followed by modulation of multiple second mes-
senger systems including but not limited to receptor coupling
to adenylyl cyclase, receptor coupling to Kþ channels, receptor
coupling to Ca2þ channels, receptor coupling to protein phos-
phatases, receptor coupling to exocytotic vesicles and receptor
coupling to the mitogen-activated protein kinase pathway.
Which second messenger is altered is dependent on the tissue-
specific distribution of ligands, receptor subtype and tissue lo-
calization of the receptors. For instance, SSTR2–5 are coupled
to Kþ channels, SSTR1 and -2 are coupled to voltage-
dependent Ca2þ channels, SSTR2 and -5 are coupled to phos-
pholipase C and SSTR1 is coupled to a Naþ/Hþ exchanger [16].
As a joint effect, all receptor subtypes inhibit adenylyl cyclase
and cAMP production.
As SST is produced at sites where the different receptors are
expressed, it is suggested that SST elicits its action especially in
an autocrine/paracrine manner. However, circulating levels of
SST derived from the gastrointestinal tract modulate insulin re-
lease, thereby eliciting a true endocrine effect [17, 18]. SST re-
ceptor activation therefore involves auto-, para- as well as
endocrine mechanisms.
Although the acute administration of SST produces a large
number of inhibitory effects, the initial response diminishes
with continued exposure to the peptide. The ability of SST
receptors to regulate their responsiveness to agonist-specific
stimulation typically involves receptor desensitization due to
uncoupling of G proteins, as well as receptor internalization
and receptor degradation. This process is dependent on recep-
tor subtype, exposure time, ligand concentration and heterolo-
gous regulation through other signalling systems [19]. The
phenomenon of receptor desensitization is important for treat-
ment with SST (see below).
Metabolism of SST
SST-14 and SST-28 are rapidly metabolized in vivo by cleav-
age through amino peptidases in blood and tissues. Experiments
FIGURE 1: SST: its precursors and cleavage products (modified
from Patel et al. [13]).
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with infusion of SST indicate that the liver and kidneys are the
main sites of elimination of the molecule (37 and 32.7%, respec-
tively). The remaining 30% of elimination is attributed to the
lungs, pancreas and blood, which together results in a metabolic
clearance rate of 30 mL/kg/min and consequently a very short
plasma half-life of 1–3 min in vivo [13].
Renal localization of SST-producing cells and SST
receptors
As mentioned above, SST-producing cells are also found in
the kidney. In vitro studies have shown, for instance, that SST is
secreted by mesangial cells and proximal tubular cells. Secretion
can be stimulated by cAMP and inhibited by epidermal growth
factor and hydrocortisone [20, 21]. Since SST is known to be an
endogenous inhibitory regulator, it is suggested that this renal-
derived SST modulates mesangial and proximal tubular cell
growth and function after binding to renal SSTRs.
There have only been a few studies investigating the renal lo-
calization of SSTRs. These studies have shown that mainly
SSTR1, -2 and -5 are expressed, especially in the distal tubules
[22, 23]. However, a more recent study found positive staining
for all receptor subtypes throughout the tubular system, except
in the collecting duct [24]. Our study group also investigated re-
nal SSTR localization. We observed SSTR2 expression mainly
in distal tubules and collecting ducts in mice, which was in
agreement with mRNA expression. In humans, we found con-
flicting data for immunostainings and mRNA expression [25].
Unfortunately, it is difficult to compare human studies since
most studies focus on only very small sections of the kidneys
and/or different antibodies were used, sometimes with distinct
antigen specificity for the SSTRs. It is important to know which
SSTR subtypes are expressed across the various segments of the
nephron segments for therapy with SST analogues, which will
be discussed later. The renal localization of SSTRs therefore
warrants further research.
Effect of SST pathway activation in renal physiology
As mentioned above, binding of SST with SSTRs can activate
pathways that can modulate renal cell function and growth.
Since renal cells both secrete SST and express SST receptors,
SST probably modulates renal cell function and growth in an
autocrine/paracrine manner. This theory is supported by the
fact that although all SSTRs have nanomolar affinity for biologi-
cally active SST (SST-14 and SST-28), systemic fasting plasma
SST concentrations have a range that is 100- to 1000-fold lower,
that is, between 0.008 and 0.02 nM, which is equivalent to 14–
32.5 pg/mL [13]. These very low concentrations are assumed to
not reach the threshold to activate SSTRs in the kidney. As SST
is partly eliminated by the kidney, it should be stated that fil-
tered SST could theoretically reach higher concentrations in
(pre)urine and in this way potentially modulate downstream tu-
bular function.
Activation of SST receptors causes inhibition of the release
of aldosterone and renin [26, 27]. Multiple studies have sug-
gested that SST is also involved in renal water handling and can
inhibit the proliferation of renal cells [28, 29]. Furthermore,
SST causes glomerular vasoconstriction, resulting in decreased
renal blood flow and consequently a reduction of the glomerular
filtration rate (GFR) [30]. These physiological processes are proba-
bly all, or at least partly, a result of the ability of SST to inhibit renal
cAMP production [31, 32]. Interestingly, one of the pivotal detri-
mental factors in the pathophysiology of ADPKD are elevated
levels of cAMP. Theoretically, SST and related agonists therefore
have the potential to induce a therapeutic effect in ADPKD.
S S T I N T H E P A T H O P H Y S I O L O G Y O F A D P K D
ADPKD is predominantly caused by a mutation in the PKD1
gene, in 80% of cases, or in the PKD2 gene, in 10% of cases. In
rare cases, other mutations are found, which have recently been
identified [33, 34]. In the remainder of cases, the mutation that
underlies the disease is not known. PKD1 encodes for the pro-
tein polycystin-1 and PKD2 for the protein polycystin-2 [35].
These proteins form the so-called polycystin complex that is lo-
calized at the base of the primary cilium, which acts as a mecha-
nosensor detecting flow in the renal tubules. When this sensor
is stimulated, calcium influx occurs from pre-urine into the cy-
toplasm of renal tubular epithelial cells and from intracellular
stores. In ADPKD, the polycystin complex is dysfunctional and
consequently calcium cannot enter the cells nor can calcium be
released from intracellular stores. Low intracellular calcium
leads to high activity of adenylyl cyclase and reduced activity of
calcium-sensitive cAMP-degrading enzyme (phosphodiesterase),
which both lead to high intracellular cAMP levels. In turn, these
high intracellular cAMP levels lead to aberrant renal
tubular epithelial cell proliferation and chloride-driven fluid
excretion in the kidney, the two key components of the process
of cyst formation and growth in ADPKD [36] (Figure 2). In PLD,
increased cholangiocyte proliferation and fluid secretion are the
key features, which are stimulated by cholangiocyte cAMP [37].
As described, SST can lead via all its receptor subtypes to
direct inhibition of adenylyl cyclase and cAMP production.
Furthermore, some SSTR subtypes can be coupled to various
phospholipase C isoforms, leading to increased Ca2þ levels,
which is an indirect mechanism by which SST can lead to
lower intracellular cAMP (Figure 2). Therefore SST has the
potential to slow disease progression in ADPKD. As described
previously, endogenous SST reaches very low plasma concen-
trations, unable to trigger SST receptors. We have observed
that SST concentrations are similar in ADPKD patients com-
pared with healthy controls (A.L. Messchendorp et al., unpub-
lished data). For this reason, SST needs to be administered to
be of therapeutic use. However, administration of endogenous
SST is of limited therapeutic potential since it is rapidly elimi-
nated in vivo. Therefore analogues have been synthesized in
which the biochemical stability of the peptide has been increased
by incorporation of modified amino acids, which typically show
selectivity for one or some of the SST receptor subtypes.
S S T A N A L O G U E S
Based on differences in ring chemistry, size and position of
bridging units, various analogues with different affinities for the
SSTR subtypes exist. The most important and clinically used
Somatostatin in ADPKD 3
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SST analogues are octreotide, lanreotide and pasireotide. There
is ample clinical experience with these drugs, as these drugs
have been used for many years in neuroendocrine disorders like
acromegaly to inhibit growth hormone secretion, but also to
treat neuroendocrine tumours by inhibiting serotonin secre-
tion. Different SST analogues, administration routes (intrave-
nous, subcutaneous, intramuscular) and dosing regimens are
used for the various indications (Table 1).
FIGURE 2: Schematic representation of the pathophysiological processes that drive cyst formation and growth in renal tubular epithelial cells of
the collecting duct in ADPKD and the mechanism of action of vasopressin V2 receptor antagonists and SST analogues. In ADPKD, the polycystin
complex (formed by the proteins PC1 and PC2 on the apical membrane) is dysfunctional, which leads to diminished calcium influx or diminished
release of calcium from intracellular stores. Low intracellular calcium levels in turn stimulate activation of adenylate cyclase (AC), which converts
adenosine triphosphate into cAMP. cAMP is an important player in several pathways that could possibly lead to cyst expansion. cAMP increases
cell proliferation via protein kinase A and activation of the Ras/Raf/ERK pathway. Furthermore, cAMP activates apical-positioned chloride chan-
nels (CFTR channels), leading to fluid secretion into the cyst lumen. cAMP production can be inhibited by blocking the vasopressin V2 receptor
(V2R), which is coupled to G stimulatory (Gs) proteins that can activate AC. Activation of the SST receptor (SSTR) can inhibit cAMP production
in a direct and indirect way. AC can be directly inhibited by the receptor-coupled G inhibitory (Gi) proteins. Activation of these Gi proteins can
also activate calcium channels and stimulate intracellular release of calcium via phospholipase C, which can restore intracellular calcium stores.
This leads indirectly to inhibition of cAMP production. Orange and grey lines indicate that the pathway is activated or inactivated, respectively.
Table 1. SST analogues and their characteristics
SST analogue Manufacturer Receptor
affinity [38]
Registered indications Administration route Half-life Dosing regimen
Octreotide
(SMS 201-995,
Sandostatin)
Novartis
Pharmaceuticals
SSTR2 >
SSTR3, -5
Acromegaly
Gastro-entero-pancreatic
endocrine tumours
Advanced neuroendocrine
tumours
TSH-secreting pituitary
adenomas
Prevention of complications
after pancreatic surgery
Acute oesophageal variceal
bleeding
IR
Subcutaneous
Intravenous
LAR
Intramuscular
IR
Subcutaneous
100 min LAR
steady state
for 3–4 weeks
IR
Subcutaneous 2–3 per day
Intravenous continuous
LAR
1 per 4 weeks
Lanreotide
(BIM 23014,
Somatuline)
Ipsen Ltd. SSTR2 >
SSTR3, -5
Acromegaly
Gastro-entero-pancreatic-
neuroendocrine tumours
Thyrotropic adenomas
ATG
Subcutaneous
SR
Intramuscular
ATG
23–30 days
SR
5 days
ATG
1 per 4 weeks
SR
1 per 7–14 days
Pasireotide
(SOM-230,
Signifor)
Novartis
Pharmaceuticals
SSTR1, -2, -3,
-5
Acromegaly
Cushing’s disease
IR
Subcutaneous
LAR
Intramuscular
IR
12 h
LAR
16 days
IR
2 per day
LAR
1 per 4 weeks
IR, immediate-release; LAR, long-acting release; ATG, autogel; SR, slow-release. The information in this table is derived from https://www.medicines.org.uk/emc/. Year of last update
2016 for octreotide and lanreotide; 2017 for pasireotide; Year of access 2018.
4 A.L. Messchendorp et al.
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Adverse effects of SST analogues
SST analogues, in general, elicit similar adverse effects, be-
cause they mostly interact with the same receptors. Most of the
receptors are found in the gastrointestinal tract and conse-
quently adverse effects are predominantly related to this tract.
Pasireotide, however, seems to lead to hyperglycaemia and
ECG abnormalities more often than the other SST analogues
[39]. Interestingly, most of these adverse effects become milder
or disappear after longer duration of the treatment. This may
be caused by receptor desensitization, as described earlier.
The most common adverse effects are summarized in Table 2.
Besides these adverse effects, there may also be ADPKD-spe-
cific adverse effects. In a recent randomized study [40], it be-
came apparent that the use of SST analogues was associated
with the development of hepatic cyst infection in patients with
ADPKD. In the Developing Interventions to halt Progression
of Autosomal dominant polycyctic Kidney disease (DIPAK) 1
trial, which included patients with later-stage ADPKD, 9 he-
patic cyst infection events in 8 subjects were noted in the 153
subjects that received lanreotide during 2.5 years of treatment
and none in the 152 subjects of the control group. A literature
review revealed that hepatic cyst infections also occurred in
other studies with SST analogues in patients with ADPKD or
PLD. Most of these complications were seen with lanreotide,
but hepatic cyst infections have also been observed with other
SST analogues [41]. The exact mechanism of hepatic cyst infec-
tions with SST analogues is unknown, but it has been suggested
that a reduction in bile flow may play a role. Also, a history of
hepatic cyst infections seems relevant. After a protocol amend-
ment excluding patients with a history of hepatic cyst infec-
tions, the incidence of this complication decreased significantly
in the aforementioned trial.
S T U D I E S W I T H S S T A N A L O G U E S I N A D P K D
Several preclinical and clinical studies have been conducted that
studied the efficacy of SST analogues to inhibit cAMP produc-
tion, hepatic and kidney cyst growth and renal function decline.
It is remarkable that the first clinical study was performed be-
fore any preclinical data were available. The rationale for the
first clinical study by Ruggenenti et al. [42] was based on an ob-
servation in a single ADPKD patient that received octreotide
for acromegaly. In this specific patient, a potential beneficial
effect of SST was considered because kidney function and kid-
ney volume remained stable during treatment with octreotide.
As there was extensive experience with SST analogues in the
treatment of neuroendocrine disorders, a Phase III study with
an SST analogue as treatment for ADPKD was started immedi-
ately, not awaiting pre-clinical data.
Pre-clinical studies
Only six experimental studies have been published that in-
vestigated the effects of SST analogues in experimental PKD.
The results of these studies are summarized in Table 3 [43–48].
The first study, published in 2007 by Masyuk et al. [43], showed
in an in vitro model of cystogenesis that octreotide inhibited
cAMP levels by 35%. In vivo kidney and hepatic cyst growth, fi-
brosis and mitotic indices were reduced in the polycystic kidney
(PCK) rat by 20–60%. After that landmark study, Spirli et al.
[44] described in 2012 that the combination of octreotide and
sorafenib (an inhibitor of tyrosine protein kinases and Raf kin-
ases), but not octreotide alone, was effective in reducing the cys-
tic area and proliferation in polycystin-2-defective mice. In
2013, Tietz Bogert et al. [45] developed a hepatic cyst model
with zebrafish embryos. Hepatic cystogenesis was inhibited
when these embryos were exposed to the SST analogue pasireo-
tide. In the same year, Masyuk et al. [46] found that octreotide
and pasireotide reduced intracellular cAMP levels and cell pro-
liferation, affecting cell cycle distribution, decreasing the growth
of cultured cysts in vitro and inhibiting hepatorenal cystogene-
sis in vivo in PCK rats and in PKD2(WS25/-) mice (a model for
ADPKD). In that study, pasireotide in the applied dose was
more potent than octreotide. In 2015, Hopp et al. [47] found in
a hypomorphic PKD1 model that treatment with tolvaptan and
pasireotide alone markedly reduced renal cyst progression and
that the combination showed an additive effect. Furthermore,
combination treatment significantly reduced cystic and fibrotic
volume and decreased cAMP to wild-type levels. They also
showed that hepatic hypertrophy could be corrected with pasir-
eotide. Lastly, Kugita et al. [48] recently investigated the efficacy
of treatment with pasireotide and octreotide in PCK rats. They
showed that pasireotide and the combination of pasireotide
with octreotide lowered kidney and liver weight, cystic volume
and renal cAMP levels. Treatment with octreotide alone did not
have an effect. In combination, these preclinical studies suggest
that SST analogues can inhibit both renal and hepatic cystogen-
esis and therefore may inhibit ADPKD progression. These stud-
ies also point to possible differences in efficacy between SST
analogues.
Clinical studies
At the moment, seven clinical studies have been completed
with SST analogues in ADPKD patients. The results of these
studies are summarized in Table 4 [42, 49–54]. These studies
have uniformly shown that SST analogues can slow the growth
in total liver volume. These studies also confirm the hypothesis
that SST analogues have a beneficial effect on the renal cystic
phenotype. Growth in total kidney volume (TKV) in subjects
using SST analogues was less than in subjects using placebo in
Table 2. Most common adverse effects of SST analogues
System Adverse effect
Gastrointestinal Diarrhoeaþþ, abdominal painþþ, nauseaþþ, con-
stipationþþ, flatulenceþþ, dyspepsiaþ, vomitingþ,
abdominal bloatingþ, steatorrhoeaþ, loose
stoolsþþ, discoloration of faecesþ
Hepatobiliary Cholelithiasisþþ, cholecystitisþ, biliary sludgeþ,
hyperbilirubinaemiaþ, acute pancreatitis
Glucoregulation Hyperglycaemiaþ, diabetes mellitusþ
Cardiac Bradycardiaþ, tachycardia, prolonged QT
intervals
þþvery often, >10%; þoften, 1–10%; sometimes, 0.1–1%; rarely, 0.01–0.1%.
Somatostatin in ADPKD 5
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most studies. However, results with respect to the rate of decline
in kidney function are equivocal. From the seven clinical stud-
ies, there were a number that showed a beneficial effect on the
rates of growth in total kidney and liver volume, but also a
greater decline in estimated GFR (eGFR) with SST analogues
than with placebo [42, 53]. However, these studies were all un-
derpowered and of too short a duration to allow firm conclu-
sions on the renoprotective effect of SST analogues. Later, the A
Long-Acting somatostatin on DIsease progression in
Nephropathy due to autosomal dominant polycystic kidney
disease (ALADIN) study was published, which included more
subjects (n¼ 79) and was of longer duration (3 years) [52]. For
the pre-specified efficacy outcomes [absolute change in TKV at
Year 3 and slope of measured GFR (mGFR) from Years 0 to 3],
no significant benefit of treatment with octreotide was observed
[52]. That no beneficial effect of SST analogues was observed on
the rate of kidney function decline in these studies may have
several explanations. First, the effect of SST analogues on the
rate of decline in kidney function is difficult to assess, because
these drugs induce a biphasic effect on GFR. Shortly after the
start of treatment, an alleged haemodynamic, reversible de-
crease in GFR is observed. Theoretically, a slower decline in the
rate of annual GFR loss occurs thereafter that reflects the struc-
tural beneficial effect that is obtained with the SST analogue.
Such a biphasic effect on eGFR has been observed with tolvap-
tan in ADPKD [6, 55] and with angiotensin-converting enzyme
inhibitors in other renal diseases. As well, the clinical studies
with SST analogues in ADPKD, which were of short duration
in general, show a greater decline in eGFR with SST analogues
than with placebo. When studying a drug with a biphasic effect
on GFR, its chronic structural renoprotective effect should be
investigated by studying the change in kidney function on
Table 3. Summary of experimental studies performed with SST analogues in PKD/PLD models
Outcome
References SST analogue Experimental design Renal phenotype Liver phenotype
Masyuk et al. [43] Octreotide In vitro: N ¼ 15
PCK bile ducts grown in 3-dimen-
sional culture with Oct or vehicle
In vivo: N ¼ 60 PCK rats treated
with Oct or vehicle
4–16 weeks
In vitro: NA
In vivo: 19–39% reduction in
kidney weight, renal cystic
volume and renal fibrosis
In vitro:
35% reduction in cAMP
levels
44% reduction in cyst growth
In vivo:
32–39% reduction in cAMP
levels
20–60% reduction in cyst
growth, fibrosis and mitotic
indices
Spirli et al. [44] Octreotide (and
sorafenib)
In vivo: N ¼ 32 Pkd2cKO mice
treated with vehicle, sorafenib,
Oct or sorafenib/Oct
8 weeks
In vivo: NA In vivo: Sorafenib/Oct:
Reduction in liver cyst vol-
ume, proliferation (Ki67),
liver weight and increased
apoptosis (CC3)
Tietz Bogert et al. [45] Pasireotide In vivo: N ¼ 800 Zebrafish injected
with morpholinos sec63, prkcsh and
pkd1a (PLD model) or control
buffer and treated with pasireotide,
VK3 or 4-PBA
In vivo: NA In vivo: Reduction of he-
patic cystogenesis
Masyuk et al. [46] Octreotide and
pasireotide
In vitro: Cholangiocytes from con-
trol and PCK rats, healthy
humans and ADPKD patients,
normally cultured or in Oct or
pasireotide
In vivo: N ¼ 27 PCK rats and N ¼
14 Pkd2ws25/- mice treated with
Oct, pasireotide or vehicle 6
weeks
In vitro: NA
In vivo: Reduction of kidney
weight (Oct 16%/pasireo-
tide 20%), cystic volume
(Oct 19%/pasireotide 30%),
fibrotic volume (Oct 18%/
pasireotide 25%)
In vitro: Reduction of cAMP
levels, cell proliferation (Oct
9.6–18.4%/pasireotide 18.6–
33.7%) and hepatic cyst ex-
pansion (Oct 1.6–2.3x/
pasireotide 2.2–4.7x)
In vivo: Reduction of liver
weight (Oct 9%/pasireotide
16%), cystic areas
(Oct 24%/pasireotide 36%),
fibrotic areas (Oct 10%/
pasireotide 19%)
Hopp et al. [47] Pasireotide
(and tolvaptan)
In vivo: N ¼ 81 Pkd1(RC/RC)
mice receiving no treatment,
tolvaptan, pasireotide or
tolvaptan/pasireotide
5 months
In vivo: Reduction in kidney
weight, cystic volume, fibrotic
volume and cAMP level with
tolvaptan/pasireotide
>tolvaptan or pasireotide
In vivo: Reduction of he-
patocyte hypertrophy by
pasireotide
Kugita et al. [48] Octreotide and
pasireotide
In vivo: N ¼ 24 PCK rats treated
with vehicle, Oct, pasireotide
or Oct/pasireotide
12 weeks
In vivo: Reduction of kidney
weight, cystic volume, prolif-
eration (Ki67) and cAMP lev-
els in pasireotide or Oct/
pasireotide
In vivo: NA
Oct, octreotide; NA, not applicable.
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treatment in a trial of longer duration. A post hoc analysis of the
ALADIN study indeed suggested that octreotide had a benefi-
cial effect on the slope in mGFR decline on treatment (Years 1–
3). Unfortunately, there were differences in baseline characteris-
tics between the two study groups in this trial that favoured the
octreotide group. Given these reasons, a definitive conclusion
on the renoprotective effect of SST analogues could still not be
reached. A larger, open-label randomized controlled trial
(RCT) was performed by our study group, investigating the
effects of 2.5 years of treatment with the SST analogue lanreo-
tide in 305 ADPKD patients with an eGFR or 30–60 mL/min/
1.73 m2 the DIPAK 1 study [54]. Given the aforementioned ex-
perience, change in kidney function on treatment was chosen as
the primary outcome. This study confirmed that lanreotide sig-
nificantly reduced liver and kidney cyst growth. However, no
attenuation of eGFR slope was observed. The rate of eGFR loss
on treatment, the primary endpoint of the study, was 3.53
with lanreotide versus 3.46 mL/min/1.73 m2/year in the con-
trol group. The difference between both groups was only 0.08
[confidence interval (95% CI) 0.71–0.56] mL/min/1.73 m2/
year and not significant (P¼ 0.81). When the secondary end-
point, annual rate of eGFR loss, was calculated using only the
pre- versus post-treatment eGFR values, no effect of lanreotide
was observed (Figure 3, left panel). A prespecified subgroup
analysis did not provide evidence that lanreotide improved the
primary outcome in any of the subgroups studied. For TKV,
however, the results were beneficial. The rate of change in
height adjusted TKV (hTKV) between the pre- and post-
treatment visit was significantly lower in the lanreotide group:
4.15%/year (95% CI 3.33–4.99) versus 5.56 (95% CI 4.76–6.36)
in the control group [difference1.33%/year (95% CI2.41 to
0.24), P¼ 0.02], corresponding with a 24% reduction in
hTKV growth rate (Figure 3, right panel). The benefit of lanreo-
tide on hTKV growth was observed in all subgroups tested. The
change in hTKV was also assessed using data from the magnetic
resonance imaging (MRI) at the end of the treatment period in-
stead of the MRI at the post-treatment visit. In that case, the dif-
ference between both groups in the hTKV growth rate was
stronger [2.14%/year (95% CI3.14 to1.12, P< 0.001), in-
dicating that after stopping lanreotide treatment, some rebound
occurs, but a beneficial effect on kidney volume is maintained
even after stopping treatment. Currently there is one clinical
study ongoing with SST analogues in ADPKD patients and
two studies that are finalized but not yet published (Table 5)
[56–58].
I S T H E R E A P L A C E F O R S S T A N A L O G U E S I N
A D P K D ?
The DIPAK 1 study provides convincing evidence that lanreo-
tide does not slow the rate of renal function decline in later-
stage ADPKD. Can we, therefore, state that there is no role for
SST analogues in the treatment of the renal phenotype of
ADPKD? This may not necessarily be true since lanreotide did
show an effect on growth in TKV and liver volume. This is sur-
prising because it is a paradigm in nephrology that effects on
TKV can be used as a surrogate marker for effects on kidney
function. The question arises whether the divergent treatment
effects on GFR and TKV are explained by trial design or are
they drug specific?
In this respect, an important difference in trial design be-
tween the DIPAK 1 and ALADIN studies was that the
ALADIN study had mGFR as the outcome (plasma clearance of
the exogenous filtration marker iohexol), whereas the DIPAK 1
study used GFR estimated by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) creatinine formula. As
is generally known, creatinine is not only filtrated by the glo-
merulus, but also partially secreted by renal tubular cells. This is
accounted for in the CKD-EPI formula [59]. Because ADPKD
is a disease characterized by an increase in renal tubular cell
FIGURE 3: Effect of the SST analogue lanreotide 120 mg subcutaneously once every 4 weeks compared with control treatment in a 2.5-year
prospective trial in patients with ADPKD. (A) The change in eGFR 16 weeks after the last dose of lanreotide (measured at a post-treatment
visit) compared with the baseline pre-treatment value [lanreotide 3.58 versus control 3.45, difference 0.13 (95% CI 1.76–1.50) mL/min/
1.73 m2/year, P¼ 0.88]. (B) The change in height-adjusted TKV (hTKV) measured at the same time points [lanreotide 4.15 versus control
5.56, difference 1.33%/year (95% CI 2.41 to 0.24), P¼ 0.02]. Boxplots show predicted mean and 25 and 75th percentiles and the lower
and upper ends of the error bars show predicted 2.5 and 97.5th percentiles, respectively, as derived from mixed model analyses (from reference
Meijer et al., JAMA in press).
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mass, it may be that the GFR estimation equations perform less
well in patients with this disease. Indeed, one study concluded
that in ADPKD, equations used to estimate GFR may be less re-
liable and may fail to detect changes in GFR over time [60].
Two other reports, however, showed that equations to estimate
GFR perform as well in ADPKD as in non-ADPKD CKD
patients [61, 62]. More importantly, when alternative measures
for kidney functions were used in the DIPAK 1 study, such as
GFR estimated with plasma cystatin C, 24-h urinary creatinine
clearance or serum urea, similar results were obtained. These
latter data indicate that the results of the DIPAK 1 study are
robust.
A second option related to trial design of the DIPAK 1 study,
which may explain why lanreotide did not preserve kidney
function, could be that patients were studied with later-stage
ADPKD. It could be that in later-stage ADPKD, SST receptors
are expressed less because of fibrosis formation, as has been
shown for the vasopressin V2 receptor in animal experiments,
[63] or that patients reached a point of ‘no return’ beyond
which other disease processes have become important and can-
not be improved by an SST analogue [64]. However, subgroup
analysis of the DIPAK 1 study showed no differences in treat-
ment effect between CKD Stages 3a and 3b, but in earlier dis-
ease the situation may be different.
The third option related to trial design could be that the dos-
age of lanreotide was suboptimal in the DIPAK 1 study. This is
less likely because a dosage of lanreotide was used that has been
shown to be effective in neuroendocrine disorders. However, it
may be that the expression of SSTRs in the kidney is too low for
SST analogues to be effective. As far as know, only one study,
performed by our study group, has investigated SSTR expres-
sion specifically in ADPKD. We observed in two conditional
Pkd1 models that SSTR2 expression levels are reduced during
kidney cyst growth. In addition, we saw a significant decrease in
SSTR2 expression in epithelia of dilated tubules and cystic epi-
thelia in mice with end-stage PKD compared with wild-type
mice. Data of human biopsies, however, are ambiguous [25].
Importantly, in the DIPAK 1 study, there was a beneficial effect
of lanreotide on TKV growth. This suggests that SSTRs are
expressed in the human ADPKD kidney.
The question then emerges whether the results of the
DIPAK 1 study are specific for lanreotide or class related?
Octreotide, for example, investigated in the ALADIN study, has
slightly more affinity for SSTR2 and SSTR3 and slightly less
affinity for SSTR5 as compared with lanreotide [39]. Whether
this results in a difference in clinical efficacy in ADPKD is
doubtful, because octreotide has been shown to be equally effec-
tive in the treatment of acromegaly compared with lanreotide,
and both drugs elicit similar adverse effects [65]. Pasireotide, on
the other hand, has more marked differences in receptor affinity
compared with lanreotide, which more likely could result in a
different treatment effect in ADPKD [66]. Also, pasireotide has
been shown to be effective in the treatment of Cushing’s disease
in contrast to octreotide [67], to be more effective in the treat-
ment of acromegaly compared with octreotide [68] and to be
more effective than octreotide in two experimental models for
ADPKD [46, 48]. More severe hyperglycaemic side effects and
frequent ECG abnormalities [39], however, are expected to
limit the widespread clinical use of pasireotide for ADPKD, a
disease for which lifelong treatment is needed.
Taking the above discussion into account, it may also be
argued that treatment effects on GFR and TKV are unrelated
(see also Figure 3). That is remarkable, because it is a para-
digm that in ADPKD, TKV is related to GFR and can be used
as a surrogate outcome, especially in trials in early stages of
the disease. However, it could also be that lanreotide has an
intrinsic nephrotoxic effect that offsets any potential benefit
that could be obtained via its effect on hTKV. However, such
a nephrotoxic effect is not known from the literature in non-
ADPKD patients. Other potential explanations could be that
the effect on TKV growth was not large enough to translate
into a functional benefit in the duration of the clinical trial,
that it takes more time before a benefit on TKV translates into
a benefit on the rate of GFR loss or that patients were included
with later-stage ADPKD, in whom growth in TKV may have a
less dominant role in causing eGFR loss than in earlier-stage
disease.
For now, we may conclude that there is no role for SST ana-
logues to preserve kidney function in ADPKD, unless future
data prove differently. However, the available evidence shows
that SST analogues do have a beneficial effect on the growth of
TKV and liver volume. ADPKD patients with a high intra-
abdominal volume and related symptoms may therefore be the
target group for treatment with these agents, to prevent or post-
pone the need for liver transplantation. Because of the possible
higher incidence of hepatic cyst infections with SST analogues,
it seems wise to exclude patients with a history of hepatic cyst
infection from such treatment.
Table 5. Summary of ongoing or finalized but as yet unpublished studies with SST analogues in ADPKD [56–58]
Institute SST analogue Trial design Inclusion criteria Clinical endpoint ClinicalTrials.gov
identifier
Mayo Clinic, Rochester, MN, USA Pasireotide
60 mg s.c., 1/28 days
N ¼ 48
RCT
12 months
PLD >4000 mL
Age >18 years
eGFR >30 mL/min/1.73 m2
Change in TLV NCT 01670110
Mario Negri Institute, Milan, Italy Octreotide
40 mg s.c., 1/28 days
N¼ 100
RCT
36 months
ADPKD
Age >18 years
eGFR 15–40 mL/min/1.73 m2
Change in mGFR
Change in TKV
NCT 01377246
Necker Hospital, Paris, France Lanreotide
120 mg s.c., 1/28 days
N¼ 180
RCT
36 months
ADPKD
Age >18 years
eGFR 30–89 mL/min/1.73 m2
Change in mGFR NCT02127437
s.c., subcutaneous.
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C O N C L U S I O N S
Among the pivotal detrimental factors in the pathophysiology
of ADPKD are elevated cAMP levels. Although therapies to
slow the rate of disease progression in ADPKD have emerged,
there is still an important unmet need for new therapies. In this
review, we show that SST analogues are theoretically promising
as therapeutic agents since these drugs inhibit cAMP produc-
tion. Both preclinical and preliminary clinical studies suggest
beneficial effects of SST analogues in the treatment of ADPKD.
However, a recent large-scale RCT showed no beneficial effect
of lanreotide on the rate of kidney function decline in patients
with later-stage ADPKD despite a beneficial effect on kidney
growth. Results of ongoing trials should be awaited before de-
finitive conclusions can be drawn with respect to renoprotec-
tion, because results may be different with other SST analogues
or in patients with earlier-stage disease. For now, treatment of
ADPKD patients with these agents should be limited to patients
with a high intra-abdominal volume and related symptoms.
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